Physiomics Regulatory News (PYC)

Physiomics plc

The Magdalen Centre

The Oxford Science Park

Robert Robinson Avenue

Oxford

OX4 4GA

UK

Tel 01865 784980

Fax 08701 671931

Physiomics plc

("Physiomics") or ("the Company")

New US Business Development Consultant.

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that Dr. David Jobes will be joining the company as Business Development Consultant. David is based on the East Coast of the USA. He has enjoyed a successful sales, research, and project management career in biotech and healthcare companies, including being co-founder and VP of Business Development at Presidio Pharmaceuticals and senior research positions at Applied Biosystems (now Life Technologies), and VaxGen. He received a Ph.D. in cell & molecular biology from Tulane University and postdoctoral training from the National Institutes of Health (NIH).

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to welcome David to our team. We expect that his knowledge of the sector coupled with his location and sales expertise will result in new US customers for Physiomics."

Enquiries:

Physiomics plc

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

WH Ireland Limited (broker/nomad)

Katy Mitchell

+44 (0) 161 832 2174

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002